Have your own idea? Try our Stock Screener
Chinese (SSE) Clinical Research and Equipment Industry Analysis
UpdatedSep 26, 2025
DataAggregated Company Financials
Companies27
- 7D-1.0%
- 3M46.3%
- 1Y98.4%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 4.2%, driven by WuXi AppTec declining 3.9%. This takes the industry's 12 month performance to a gain of 101%. As for the next few years, earnings are expected to grow by 21% per annum.
Industry Valuation and Performance
Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Sep 2025 | CN¥625.7b | CN¥92.1b | CN¥17.4b | 74.8x | 35.9x | 6.8x |
| Sun, 24 Aug 2025 | CN¥586.0b | CN¥92.5b | CN¥17.5b | 61.4x | 33.4x | 6.3x |
| Tue, 22 Jul 2025 | CN¥513.0b | CN¥89.8b | CN¥15.4b | 53.7x | 33.4x | 5.7x |
| Thu, 19 Jun 2025 | CN¥422.5b | CN¥89.8b | CN¥15.4b | 46.9x | 27.5x | 4.7x |
| Sat, 17 May 2025 | CN¥392.6b | CN¥89.6b | CN¥15.5b | 44.9x | 25.4x | 4.4x |
| Mon, 14 Apr 2025 | CN¥367.7b | CN¥88.5b | CN¥14.0b | 38.3x | 26.2x | 4.2x |
| Wed, 12 Mar 2025 | CN¥434.2b | CN¥89.0b | CN¥11.3b | 43.8x | 38.3x | 4.9x |
| Fri, 07 Feb 2025 | CN¥378.5b | CN¥88.1b | CN¥11.2b | 39.2x | 33.7x | 4.3x |
| Sun, 05 Jan 2025 | CN¥347.1b | CN¥87.8b | CN¥11.2b | 34.2x | 31x | 4x |
| Tue, 03 Dec 2024 | CN¥374.4b | CN¥87.8b | CN¥11.2b | 39.9x | 33.5x | 4.3x |
| Thu, 31 Oct 2024 | CN¥372.6b | CN¥88.3b | CN¥11.5b | 37.1x | 32.3x | 4.2x |
| Sat, 28 Sep 2024 | CN¥333.6b | CN¥88.2b | CN¥12.4b | 31.1x | 27x | 3.8x |
| Mon, 26 Aug 2024 | CN¥262.3b | CN¥87.4b | CN¥12.3b | 23.8x | 21.3x | 3x |
| Wed, 24 Jul 2024 | CN¥282.6b | CN¥88.3b | CN¥13.4b | 26.9x | 21.1x | 3.2x |
| Fri, 21 Jun 2024 | CN¥294.8b | CN¥88.3b | CN¥13.4b | 26.1x | 22x | 3.3x |
| Sun, 19 May 2024 | CN¥330.3b | CN¥88.3b | CN¥13.3b | 29.1x | 24.8x | 3.7x |
| Tue, 16 Apr 2024 | CN¥316.6b | CN¥90.3b | CN¥15.0b | 31.7x | 21.1x | 3.5x |
| Thu, 14 Mar 2024 | CN¥373.4b | CN¥90.5b | CN¥15.5b | 32.7x | 24.1x | 4.1x |
| Sat, 10 Feb 2024 | CN¥349.1b | CN¥91.1b | CN¥16.1b | 29.9x | 21.7x | 3.8x |
| Mon, 08 Jan 2024 | CN¥448.6b | CN¥91.1b | CN¥16.1b | 37.1x | 27.9x | 4.9x |
| Wed, 06 Dec 2023 | CN¥492.7b | CN¥91.1b | CN¥16.1b | 36.8x | 30.6x | 5.4x |
| Fri, 03 Nov 2023 | CN¥530.3b | CN¥91.1b | CN¥16.1b | 37.8x | 32.9x | 5.8x |
| Sun, 01 Oct 2023 | CN¥520.4b | CN¥92.0b | CN¥18.3b | 35.6x | 28.4x | 5.7x |
| Tue, 29 Aug 2023 | CN¥486.2b | CN¥92.2b | CN¥18.8b | 33.6x | 25.9x | 5.3x |
| Thu, 27 Jul 2023 | CN¥469.7b | CN¥91.3b | CN¥18.5b | 34.2x | 25.4x | 5.1x |
| Sat, 24 Jun 2023 | CN¥454.7b | CN¥91.3b | CN¥18.5b | 33.9x | 24.6x | 5x |
| Mon, 22 May 2023 | CN¥499.2b | CN¥91.3b | CN¥18.5b | 39.4x | 27x | 5.5x |
| Wed, 19 Apr 2023 | CN¥588.7b | CN¥91.2b | CN¥19.1b | 51.9x | 30.8x | 6.5x |
| Fri, 17 Mar 2023 | CN¥566.4b | CN¥85.6b | CN¥20.0b | 48.9x | 28.4x | 6.6x |
| Sun, 12 Feb 2023 | CN¥668.5b | CN¥86.6b | CN¥20.8b | 55.5x | 32.1x | 7.7x |
| Tue, 10 Jan 2023 | CN¥648.9b | CN¥86.6b | CN¥20.8b | 54x | 31.2x | 7.5x |
| Thu, 08 Dec 2022 | CN¥592.5b | CN¥86.6b | CN¥20.8b | 51.6x | 28.5x | 6.8x |
| Sat, 05 Nov 2022 | CN¥623.4b | CN¥86.5b | CN¥20.8b | 51.9x | 29.9x | 7.2x |
| Mon, 03 Oct 2022 | CN¥536.7b | CN¥78.2b | CN¥16.9b | 44.3x | 31.7x | 6.9x |
Price to Earnings Ratio
31.7x
Current Industry PE
- Investors are optimistic on the Chinese Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 35.1x which is higher than its 3-year average PE of 28.5x.
- The 3-year average PS ratio of 5.1x is lower than the industry's current PS ratio of 6.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 5.6% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Comparison
How does Chinese Clinical Research and Equipment compare with similar industries?
| CN Market | 0.98% | |
| Healthcare | -1.55% | |
| Life Sciences | -1.01% | |
| Clinical Research and Equipment | -1.01% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 300347 Hangzhou Tigermed Consulting | CN¥60.70 | 2.1% +CN¥1.1b | 9.2% | PE175.6x | |
| 688131 Shanghai Haoyuan Chemexpress | CN¥79.38 | 4.9% +CN¥793.3m | 209.6% | PE59.5x | |
| 688710 Shanghai InnoStar Bio-tech | CN¥49.52 | 7.1% +CN¥462.4m | 100.7% | PE189x | |
| 688238 Obio Technology (Shanghai) | CN¥8.00 | 3.6% +CN¥176.5m | 83.5% | PS19.8x | |
| 688046 GemPharmatech | CN¥19.10 | 2.1% +CN¥159.5m | 64.1% | PE74.8x |